Table S1. Inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) for BRCA1 and BRCA2 germline testing. Table S2. Genotype, phenotype and cancer family history of familial BC index patients carrying heterozygous germline loss-of-function (LoF) variants in the BARD1 gene (transcript NM_000465.3). Table S3. Prevalence of heterozygous germline LoF variants identified in the BARD1 gene (transcript NM_000465.3). Table S4. Potentially damaging rare missense variants identified in the BARD1 gene (transcript NM_000465.3). (DOCX 76 kb
Additional file 3: Supplementary Table S8, Supplementary Table S9, Supplementary Table S10, Suppleme...
Table S4. Clinical Dataset. Spreadsheet with code-book, containing pathogenic germline gene mutation...
Ndiaye R BRCA2 Supplementary Material. Table S1 Primers used for BRCA1 coding exons PCR amplificatio...
Table S3. Correlation between clinical risk factors of hereditary breast cancer and having pathogeni...
Figure S1. Calling somatic methylation status. Figure S2. Example LOH events. Figure S3. Genes frequ...
Taqman assays used for CNV assessment at 7 gene loci. Table S3. Cancer-predisposing genes disrupted ...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Table S3. Breast cancer tumour phenotypes according to BRCA1 and BRCA2 mutated cases. (DOC 14 kb
Additional file 2: Supplementary Methods, Supplementary Table S5, Supplementary Table S6, Supplement...
Pathogenic mutations in BRCA1 (NM_007294.3) and BRCA2 (NM_000059.3) genes (n = 96) detected in 398 p...
Deleterious BRCA1/2 germline mutations in Pakistani patients with TNBC. (DOCX 24Â kb
Breast cancer (BC) patients considered for the study, their age at diagnosis and the number of affec...
Additional file 3: Supplementary Table S8, Supplementary Table S9, Supplementary Table S10, Suppleme...
Table S4. Clinical Dataset. Spreadsheet with code-book, containing pathogenic germline gene mutation...
Ndiaye R BRCA2 Supplementary Material. Table S1 Primers used for BRCA1 coding exons PCR amplificatio...
Table S3. Correlation between clinical risk factors of hereditary breast cancer and having pathogeni...
Figure S1. Calling somatic methylation status. Figure S2. Example LOH events. Figure S3. Genes frequ...
Taqman assays used for CNV assessment at 7 gene loci. Table S3. Cancer-predisposing genes disrupted ...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Supplementary Methods. Table S1. Clinical and pathological characteristics, BRCA sequencing and MLPA...
Table S3. Breast cancer tumour phenotypes according to BRCA1 and BRCA2 mutated cases. (DOC 14 kb
Additional file 2: Supplementary Methods, Supplementary Table S5, Supplementary Table S6, Supplement...
Pathogenic mutations in BRCA1 (NM_007294.3) and BRCA2 (NM_000059.3) genes (n = 96) detected in 398 p...
Deleterious BRCA1/2 germline mutations in Pakistani patients with TNBC. (DOCX 24Â kb
Breast cancer (BC) patients considered for the study, their age at diagnosis and the number of affec...
Additional file 3: Supplementary Table S8, Supplementary Table S9, Supplementary Table S10, Suppleme...
Table S4. Clinical Dataset. Spreadsheet with code-book, containing pathogenic germline gene mutation...
Ndiaye R BRCA2 Supplementary Material. Table S1 Primers used for BRCA1 coding exons PCR amplificatio...